Analysts’ Recommendations for Allergan on April 27



Wall Street analysts’ estimates

Wall Street analysts expect Allergan’s (AGN) 1Q18 revenues to increase ~0.6% to $3.59 million, compared to revenues of $3.57 million during 1Q17. Its earnings per share (or EPS) are estimated to be $3.36 for 1Q18, compared to earnings per share of $3.35 for 1Q17.

The chart above shows Wall Street recommendations for Allergan stock over the last 12 months.

Article continues below advertisement

Analysts’ ratings

Allergan’s stock price has fallen ~33.0% over the last 12 months, and it has fallen ~1.9% in 2018 year-to-date. Analysts’ estimates show that the stock has a potential to return ~31.0% over the next 12 months. These recommendations show a 12-month target price of $210.32 per share compared to its price of $160.53 per share on April 26.

Analysts’ recommendations

On April 27, 25 Wall Street analysts were tracking Allergan. Of these 25 analysts, five recommended a “strong buy,” 11 recommended a “buy,” and nine analysts recommended a “hold” for Allergan. None of the analysts recommended a “sell” for Allergan stock. 

The consensus rating for Allergan stands at ~2.2, which represents a strong buy for long-term growth investors and a moderate buy for momentum investors.

Allergan’s valuations

On April 27, Allergan traded at a forward price-to-earnings (or PE) multiple of 10.0x, compared to the industry average of 10.1x. The company trades at a forward EV-to-EBITDA[1. enterprise value to earnings before interest, tax, depreciation, and amortization] multiple of 10.9x compared to the industry average of 10.0x.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.5% of its total investments in Allergan (AGN), 4.8% in Merck & Co. (MRK), 4.4% in Pfizer (PFE), and 4.1% in Mylan NV (MYL).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!


More From Market Realist